MX2017016337A - Tratamiento de carcinoma de linea media nut. - Google Patents

Tratamiento de carcinoma de linea media nut.

Info

Publication number
MX2017016337A
MX2017016337A MX2017016337A MX2017016337A MX2017016337A MX 2017016337 A MX2017016337 A MX 2017016337A MX 2017016337 A MX2017016337 A MX 2017016337A MX 2017016337 A MX2017016337 A MX 2017016337A MX 2017016337 A MX2017016337 A MX 2017016337A
Authority
MX
Mexico
Prior art keywords
nmc
treatment
midline carcinoma
bromodomain inhibitor
nut midline
Prior art date
Application number
MX2017016337A
Other languages
English (en)
Spanish (es)
Inventor
B Landau Steven
H Kagey Michael
Original Assignee
Tensha Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tensha Therapeutics Inc filed Critical Tensha Therapeutics Inc
Publication of MX2017016337A publication Critical patent/MX2017016337A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G01N2333/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MX2017016337A 2015-06-26 2016-06-24 Tratamiento de carcinoma de linea media nut. MX2017016337A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562185203P 2015-06-26 2015-06-26
PCT/US2016/039270 WO2016210275A1 (en) 2015-06-26 2016-06-24 Treatment of nut midline carcinoma

Publications (1)

Publication Number Publication Date
MX2017016337A true MX2017016337A (es) 2018-11-22

Family

ID=56409188

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017016337A MX2017016337A (es) 2015-06-26 2016-06-24 Tratamiento de carcinoma de linea media nut.

Country Status (14)

Country Link
US (1) US20180193350A1 (enExample)
EP (1) EP3314005A1 (enExample)
JP (1) JP2018520124A (enExample)
KR (1) KR20180035785A (enExample)
CN (1) CN107787227A (enExample)
AR (1) AR105124A1 (enExample)
AU (1) AU2016283020A1 (enExample)
BR (1) BR112017028178A2 (enExample)
CA (1) CA2989313A1 (enExample)
HK (1) HK1252062A1 (enExample)
IL (1) IL256186A (enExample)
MA (1) MA42249A (enExample)
MX (1) MX2017016337A (enExample)
WO (1) WO2016210275A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2799403C (en) 2010-05-14 2020-01-21 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating leukemia
HUE031073T2 (en) 2010-05-14 2017-06-28 Dana Farber Cancer Inst Inc Thieno triazolo-diazepine compounds for the treatment of neoplasia
RU2016122654A (ru) 2013-11-08 2017-12-14 Дана-Фарбер Кэнсер Инститьют, Инк. Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка
CA2940472A1 (en) 2014-02-28 2015-09-03 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia
EA033325B1 (ru) 2014-10-27 2019-09-30 Тэнша Терапеутикс, Инк. Ингибиторы бромодомена
WO2024123929A1 (en) * 2022-12-06 2024-06-13 Bioventures, Llc Development of potent dual hdac/brd4 inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
CN101910182B (zh) 2007-12-28 2013-07-17 田边三菱制药株式会社 抗癌剂
GB0919431D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
EP3050885B1 (en) 2009-11-05 2017-10-18 GlaxoSmithKline LLC Benzodiazepine bromodomain inhibitor
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919426D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
ES2652304T3 (es) 2009-11-05 2018-02-01 Glaxosmithkline Llc Compuesto de benzodiacepina novedoso
HUE031073T2 (en) 2010-05-14 2017-06-28 Dana Farber Cancer Inst Inc Thieno triazolo-diazepine compounds for the treatment of neoplasia
JP5715241B2 (ja) * 2010-05-14 2015-05-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法
WO2011161031A1 (en) 2010-06-22 2011-12-29 Glaxosmithkline Llc Benzotriazolodiazepine compounds inhibitors of bromodomains
WO2012075456A1 (en) 2010-12-02 2012-06-07 Constellation Pharmaceuticals Bromodomain inhibitors and uses thereof
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
EP2705039B1 (en) 2011-05-04 2017-07-26 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
EP2721031B1 (en) 2011-06-17 2016-01-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
CA2940472A1 (en) 2014-02-28 2015-09-03 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia

Also Published As

Publication number Publication date
BR112017028178A2 (pt) 2018-08-28
CN107787227A (zh) 2018-03-09
AU2016283020A1 (en) 2018-01-04
MA42249A (fr) 2018-05-02
KR20180035785A (ko) 2018-04-06
IL256186A (en) 2018-02-28
WO2016210275A1 (en) 2016-12-29
EP3314005A1 (en) 2018-05-02
CA2989313A1 (en) 2016-12-29
US20180193350A1 (en) 2018-07-12
AR105124A1 (es) 2017-09-06
HK1252062A1 (zh) 2019-05-10
JP2018520124A (ja) 2018-07-26

Similar Documents

Publication Publication Date Title
MX2017016337A (es) Tratamiento de carcinoma de linea media nut.
MX2022012424A (es) Tratamiento del sindrome del cromosoma x fragil con canabidiol.
MX2021008044A (es) Metodos para el tratamiento de condiciones asociadas con la activacion del complemento dependiente de masp-2.
PH12019501010A1 (en) Arginase inhibitor combination therapies
MX2022001757A (es) Inhibidores de muerte programada 1 (pd-19)/ligando de muerte programada 1 (pd-l1) para el tratamiento de cancer.
EP4253412A3 (en) Inhibition of cytokine-induced sh2 protein in nk cells
PH12018501009A1 (en) Methods for treating conditions associated with masp-2 dependent complement activation
MX383691B (es) Método de tratamiento de cáncer asociado con una mutación de ras.
ZA202005388B (en) Methods of treating ulcerative colitis
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
BR112014028041A2 (pt) tratamento de obesidade hipotalâmica com inibidores de metap2
EA036102B9 (ru) Терапевтические средства с углевод-опосредованной адресной доставкой
CA2928278C (en) SW-SAGD INJECTION PROCESS BETWEEN HEEL AND TOE
MX2020002216A (es) Metodos y composiciones para detectar y tratar endometriosis.
WO2016094834A3 (en) A method for treating a complement mediated disorder caused by an infectious agent in a patient
PH12017500615A1 (en) Ophthalmic composition comprising cyclosporine and trehalose
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
EA201891514A1 (ru) Комбинированная терапия ингибитором бромодомена и экстратерминального белка
PH12018501443A1 (en) Methods of administering hepcidin
BR112019005040A2 (pt) aplicação de pridopidina para tratamento de síndrome de rett
EA201792641A1 (ru) Ингибитор оси igfbp3/tmem219 и диабет
MX382044B (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés.
MX2016006584A (es) Métodos y composiciones para tratar los depósitos de amiloide.
MX2019012659A (es) Metodos para tratar ateroesclerosis con neutralizadores gamma-cetoaldehido.
TW201613610A (en) Use of ginsenoside M1 for treating lupus nephritis